Amyotrophic Lateral Sclerosis Treatment Market to Reach $1.38 Billion by 2035, Growing at 5.2% CAGR | Biogen, Ionis Pharmaceuticals, Pfizer Among Key Players

The global amyotrophic lateral sclerosis treatment market, valued at USD 0.79 billion in 2024, will grow to USD 1.38 billion by 2035, advancing at a compound annual growth rate of 5.2% over the forecast period. Rising disease incidence, a deepening clinical pipeline, and a wave of regulatory approvals are pushing this long-underserved market toward sustained commercial expansion. For pharmaceutical companies, investors, and healthcare strategists, the next decade presents a concrete opportunity in a therapeutic area that has historically had few approved options.

To explore the complete findings, request a free sample of the report at:
https://www.rootsanalysis.com/reports/amyotrophic-lateral-sclerosis-treatment-market/request-sample.html

MARKET OVERVIEW
Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder affecting the nerve cells that control voluntary muscle movement. The disease begins with symptoms such as muscle weakness and stiffness, then advances to permanent paralysis. With approximately 5,000 new cases diagnosed annually in the United States alone and roughly 30,000 Americans living with ALS at any given time, according to the CDC's National ALS Registry, the medical burden is substantial and the gap in effective treatment remains wide.

That gap is beginning to close. In April 2023, the FDA granted accelerated approval to QALSODY (tofersen), developed by Biogen based on a drug discovered by Ionis Pharmaceuticals, for the treatment of SOD1-ALS. The European Medicines Agency followed with its own approval in May 2024. QALSODY became the third targeted therapy approved for ALS, a milestone that has signaled to the broader industry that regulatory pathways for this indication are viable. The approval has catalyzed a new cycle of research investment across both large pharmaceutical companies and well-funded biotechs.

At the institutional level, the National Institutes of Health announced the launch of the Accelerating Medicines Partnership for ALS (AMP ALS) in May 2024, a public-private collaboration bringing together NIH, the National Institute of Neurological Disorders and Stroke, the FDA, the Critical Path Institute, and multiple industry partners. The initiative carries a combined commitment of USD 60 million, focused squarely on early diagnosis tools and disease-modifying therapies, areas where commercial development has historically stalled.

KEY GROWTH DRIVERS
Rising Disease Burden Creates Urgent Commercial Demand The CDC reports approximately 5,000 new ALS diagnoses in the United States every year, and global prevalence continues to grow as populations age. This rising patient population is generating direct demand for new therapies, particularly those capable of slowing disease progression rather than managing symptoms. Every new diagnosis represents an unmet therapeutic need, and the cumulative weight of that demand is one of the clearest structural drivers of market growth.

Expanding Clinical Pipeline Approaching Commercial Readiness The ALS pipeline made measurable progress in 2024. In August, the University of Birmingham and Sweden-based TikoMed reported phase II results for the investigational drug ILB. NeuroSense Therapeutics presented 12-month data from a phase IIb trial for PrimeC, showing slower disease progression and improved survival rates. India-based Zydus Lifesciences completed phase II clinical trials for Usnoflast, an oral small molecule NLRP3 inhibitor, in September 2024. As these molecules advance, commercialization timelines are compressing and revenue projections are becoming more concrete.

Government and Institutional Investment Accelerating R&D The USD 60 million AMP ALS partnership, combined with the FDA's Rare Neurodegenerative Disease Grant Program, announced in June 2024, is directing capital toward early-stage research that commercial entities cannot yet justify funding alone. These programs de-risk the development environment, reduce the time-to-trial for experimental compounds, and signal long-term regulatory commitment, all of which attract private investment into the space.

Regulatory Approvals Opening the Commercial Door The accelerated approval of QALSODY established a precedent that ALS drugs can reach patients faster through conditional pathways when early clinical signals are promising. That precedent is reshaping how drug developers approach the regulatory strategy for ALS candidates, making the approval pathway more predictable and the development investment more attractive.

Growing Venture Capital Interest in Precision Therapies In March 2023, QurAlis raised USD 88 million in a Series B funding round to advance precision medicine for ALS, including its lead candidates QRL-201 and QRL-101. This level of private capital flowing into an indication once considered too difficult for commercial development reflects a broader market re-rating, as genetic insights and targeted delivery mechanisms make precision ALS therapy increasingly feasible.

MARKET SEGMENTATION
The amyotrophic lateral sclerosis treatment market breaks down by type of ALS, treatment modality, distribution channel, and geography. By ALS type, sporadic ALS dominates with 86% of current revenue, reflecting both the higher prevalence (90 to 95% of all ALS cases are sporadic) and the commercial success of drugs such as edaravone (Radicava) and AMX0035 (Relyvrio), which showed efficacy specifically in this patient population. Familial ALS, though a smaller segment today, will grow at a higher CAGR through 2035 as genetic research accelerates and targeted therapies for gene-specific mutations reach the clinic.

By treatment type, medication holds the largest share at 22% of total market revenue, driven by FDA-approved small molecules and antisense oligonucleotide therapies. Stem cell therapy is an emerging category of note; Mitsubishi Chemical Group's CL2020 demonstrated safety in a Japanese phase II trial before development was paused due to a change in business focus, illustrating both the segment's potential and the development risks. By distribution channel, hospitals currently capture the majority of revenue given ALS's clinical complexity and the need for specialist oversight, but retail and online pharmacy channels will grow faster as telehealth adoption expands medication access.

For a detailed segmentation breakdown and forecast data, download a free sample report at:
https://www.rootsanalysis.com/reports/amyotrophic-lateral-sclerosis-treatment-market/request-quote.html

REGIONAL INSIGHTS
North America leads the global amyotrophic lateral sclerosis treatment market with 31.0% of total revenue in 2024. The United States accounts for the majority of that share, supported by advanced neurology infrastructure, a high rate of specialist diagnosis, and the availability of multiple FDA-approved therapies including Qalsody, Radicava, and Relyvrio. Active R&D programs from companies headquartered in the US, combined with institutional programs like AMP ALS, continue to reinforce North America's position as the market's commercial and scientific center.

Asia-Pacific will grow at the highest CAGR through 2035. Governments across the region are increasing investment in healthcare infrastructure for neurodegenerative diseases, and awareness of ALS is rising among both clinicians and patients. Japan is particularly active, with domestic drug development programs and clinical trials already underway. Broader market expansion in China, India, and South Korea will be driven by improving diagnostic access and growing healthcare spending on rare disease management.

Europe holds meaningful share, supported by EMA approvals and strong academic research networks, and the Middle East, North Africa, and Latin America represent smaller but developing markets as rare disease awareness programs gain institutional backing.

COMPETITIVE LANDSCAPE
Key companies profiled in the Roots Analysis report include Avanir Pharmaceuticals, Anavex Life Sciences, AB Science, BrainStorm Therapeutics, Biogen, Biohaven Pharmaceutical Holding Company, Bausch Health Companies, Biocytogen, Cytokinetics, Genentech, GW Pharmaceuticals, Ionis Pharmaceuticals, Mitsubishi Chemical Corporation, Novartis International, Neuraltus Pharmaceuticals, Ono Pharmaceutical, Pfizer, Regeneron Pharmaceuticals, and Sanofi.

The competitive environment is highly fragmented, with a mix of large pharma, mid-cap biotech, and well-funded startups all active in ALS drug development. The primary battleground is scientific differentiation: companies are competing on mechanism of action, patient subpopulation specificity, and clinical endpoint outcomes rather than price alone. Licensing and partnership activity remains a central strategy, as seen in the Biogen-Ionis collaboration that produced Qalsody, and more such deals are expected as the pipeline matures. The setback of Relyvrio's withdrawal after a failed phase III trial also underscores that regulatory momentum can reverse, making clinical data quality the most critical competitive asset in this market.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/amyotrophic-lateral-sclerosis-treatment-market.html

Contact Details for Roots Analysis
Chief Executive: Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/

About Roots Analysis
Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.